Heart failure drug trial ends early – only 4 patients enrolled
NCT ID NCT06581159
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This was a very early (Phase 1) study testing a drug called HS135 in obese patients who have both pulmonary hypertension and a type of heart failure called HFpEF. The trial was terminated after enrolling only 4 people, so we have no useful information on whether HS135 is safe or effective. The main goal was to check for side effects and measure how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS135
What this could lead to
If it had worked, HS135 might have pointed toward a new treatment for obese patients with pulmonary hypertension and heart failure.
What could go wrong
This trial was terminated early with only 4 participants, so no conclusions can be drawn. It was a very early Phase 1 safety study, and the drug may not have been effective or safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site-104
Phoenix, Arizona, 85016, United States
-
Site-105
Kansas City, Missouri, 64111, United States